IGF1 and acromegaly: We found that patients with active acromegaly during c-Peg-V therapy carried significantly higher IGF-I x ULN levels at the start of second line therapies (IGF-I x ULN: 3.4; IQR: 2.3), with respect to those treated with m-Peg-V (IGF-I x ULN: 2.3; IQR: 1.2, p = 0.004) and with Pasireotide Lar (IGF-I x ULN: 2; IQR: 0.7, p = 0.04).